IMMVIRA

immvira-logo

Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.

#SimilarOrganizations #People #Financial #Event #Website #More

IMMVIRA

Industry:
Clinical Trials

Founded:
2015-01-01

Address:
Shenzhen, Guangdong, China

Country:
China

Website Url:
http://www.immvira-theravir.com

Total Employee:
1+

Status:
Active

Contact:
(0755)28291816

Total Funding:
90.49 M USD

Technology used in webpage:
SPF Microsoft Azure DNS China Telecom Tencent QQ Mail Xinnet DNS


Similar Organizations

affimed-logo

Affimed

Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

genetron-health-logo

Genetron Health

Genetron Health is a world-leading expert in precision medicine.

Current Employees Featured

carl-yeung_image

Carl Yeung
Carl Yeung CFO @ Immvira
CFO

grace-zhou_image

Grace Zhou
Grace Zhou CEO/CSO & Founder @ Immvira
CEO/CSO & Founder

Founder


grace-zhou_image

Grace Zhou

Investors List

gl-ventures_image

GL Ventures

GL Ventures investment in Series C - Immvira

windigital-capital_image

WinDigital Capital

WinDigital Capital investment in Series C - Immvira

lanting-capital_image

Lanting Capital

Lanting Capital investment in Series C - Immvira

octagon-capital-partners_image

Octagon Capital Partners

Octagon Capital Partners investment in Series C - Immvira

hillhouse-capital_image

Hillhouse Capital Group

Hillhouse Capital Group investment in Series C - Immvira

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series C - Immvira

greater-bay-area-homeland-development-fund_image

Greater Bay Area Homeland Development Fund

Greater Bay Area Homeland Development Fund investment in Series C - Immvira

china-merchants-capital_image

China Merchants Capital

China Merchants Capital investment in Series C - Immvira

shanghai-healthcare-capital_image

Shanghai Healthcare Capital

Shanghai Healthcare Capital investment in Series B - Immvira

cowin-capital_image

Cowin Capital

Cowin Capital investment in Series B - Immvira

Key Employee Changes

Date New article
2020-07-01 Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer

Official Site Inspections

http://www.immvira-theravir.com Semrush global rank: 4.26 M Semrush visits lastest month: 2.73 K

Unable to get host informations!!!

Loading ...

More informations about "Immvira"

ไบฆ่ฏบๅพฎ-ImmVira

ImmVira is a biotechnology company focused on development of new generation novel drug vectors driven by clinical benefits in oncology and non-oncology fields. Leveraging naturally โ€ฆSee details»

Immvira - Crunchbase Company Profile & Funding

Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of โ€ฆSee details»

ImmVira - LinkedIn

ImmVira | 223 followers on LinkedIn. A company focusing on developing aboard range of anti-cancer therapies | VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by โ€ฆSee details»

ๅ…ณไบŽๆˆ‘ไปฌ - immviragroup.com

ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors driven by clinical benefits in oncology and non-oncology fields. Leveraging โ€ฆSee details»

Immvira Pharma Co. Ltd | Reagan-Udall Foundation

ImmVira is a biotechnology company focused on development of new generation novel drug vectors driven by clinical benefits in oncology and non-oncology fields. T3011 is a replication โ€ฆSee details»

Immvira Company Profile | Management and Employees List

Immvira Profile and History ImmVira is a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, โ€ฆSee details»

ImmVira | VentureRadar

Immvira's mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic โ€ฆSee details»

ImmVira Company Profile - Office Locations, Competitors ... - Craft

ImmVira is a company that develops biopharmaceutical technology in the field of immunotherapy. The company provides medical solutions to treat cancer and tumor. It offers a product called โ€ฆSee details»

Press Release - immviragroup.com

SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for oncolytic โ€ฆSee details»

Immvira Co. Ltd. - BioCentury Company Profiles - BCIQ

Apr 21, 2023 Immvira Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»

ImmVira and Shanghai Pharma Announce Clinical Collaboration โ€ฆ

Aug 6, 2020 Immvira Co., Ltd. was founded on May 18, 2015 by six scientists in the field of "tumor's oncolytic immunity" from the United States. The company develops innovative drugs โ€ฆSee details»

ImmVira enters clinical development in combination therapy of โ€ฆ

Apr 19, 2022 MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of โ€ฆSee details»

ImmVira enters clinical development in combination therapy of โ€ฆ

Apr 20, 2022 ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors. Our advanced engineering created vectors that are highly โ€ฆSee details»

Immvira moves intravenous oHSV into phase II for cancer

Nov 13, 2023 Immvira Group Co. plans to progress its intravenous oncolytic herpes simplex virus (oHSV) MVR-T3011-IV to phase II trials after completing a phase I study in the U.S. in โ€ฆSee details»

ImmVira's New-Generation Vector Poised to Enable CAR-T โ€ฆ

Jan 25, 2022 ImmVira will continue to adhere to a science-driven, original innovations and patient-focused philosophy, to continue research and development of new viral vectors drugs. โ€ฆSee details»

ImmVira and Shanghai Pharma Announce Clinical Collaboration

Aug 6, 2020 Immvira Co., Ltd. was founded on May 18, 2015 by six scientists in the field of "tumor's oncolytic immunity" from the United States. The company develops innovative drugs โ€ฆSee details»

ImmVira's MVR-T3011 IV completed first 2 cohorts dose โ€ฆ

ImmVira's CEO Dr. Guoying Zhou said, "The good news from MVR-T3011 IV clinical study is inspiring. Leveraging our proprietary OvPENS new drug R&D platform, we will continue to โ€ฆSee details»

FDA Fast Tracks ImmVira's Oncolytic Herpes Simplex Virus Therapy โ€ฆ

Mar 21, 2024 ImmVira's oncolytic herpes simplex virus (oHSV) therapy MVR-T3011 IT for intratumoral injection has been granted Fast Track designation by the FDA to treat patients โ€ฆSee details»

ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus โ€ฆ

Jul 21, 2022 Shenzhen ImmVira announced its IV oncolytic herpes simplex virus (oHSV) therapy showed promising biodistribution after completing the first three dose escalations in a US trial โ€ฆSee details»

ImmVira's MVR-T3011 Obtained NMPA's Approval for Intravenous ...

SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval โ€ฆSee details»

linkstock.net © 2022. All rights reserved